← Human Trials & Peer-Reviewed Studies
Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes
Plain-language guide to PMID 21660077 (2011): randomized controlled trial study of Exenatide and Glucagon.
Key Facts
- PMID
- 21660077
- Journal
- Obesity (Silver Spring, Md.)
- Year
- 2011
- Study type
- Randomized Controlled Trial
- Authors
- Sathyanarayana P et al. (6 authors)
- DOI
- 10.1038/oby.2011.152
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Exenatide and Glucagon, published as a randomized controlled trial.
The researchers examined the effects of combined pioglitazone (peroxisome proliferator-activated receptor-γ (PPAR-γ) agonist) and exenatide (GLP-1 receptor agonist) therapy on hepatic fat content and plasma adiponectin levels in patients with type 2 diabetes (T2DM).
At baseline, hepatic fat content and plasma adiponectin levels were similar between the two treatment groups.
Who Took Part
By PubMed's age tags, the people studied were middle-aged adults.
How the Study Was Run
In design terms this was a randomized study.
Because people in this Exenatide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
The methods mention a period of 12 months.
What Was Measured
The researchers examined the effects of combined pioglitazone (peroxisome proliferator-activated receptor-γ (PPAR-γ) agonist) and exenatide (GLP-1 receptor agonist) therapy on hepatic fat content and plasma adiponectin levels in patients with type 2 diabetes (T2DM).
At baseline, hepatic fat content and plasma adiponectin levels were similar between the two treatment groups.
Topics PubMed links to this paper include Adiponectin, Adipose Tissue, Alanine Transaminase, Aspartate Aminotransferases, Biomarkers, Blood Glucose and Body Mass Index.
What This Means in Plain Language
The paper is a randomized study of Exenatide and Glucagon over 12 months.
The publication is from 2011 (Obesity (Silver Spring, Md.)), a journal based in United States.
More context: the Exenatide compound page and the Glucagon compound page, all human trials.
Our Notes on the Compounds
Exenatide: A 39-amino-acid GLP-1 receptor agonist first identified in Gila monster venom; sold as Byetta and Bydureon for type 2 diabetes.
Glucagon: A 29-amino-acid pancreatic hormone that raises blood glucose; used as a rescue medicine for severe low blood sugar and as a diagnostic aid.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.